455955-27-8

Basic information

• Product Name: 2-CHLORO-5-FLUOROQUINOLINE
• Synonyms: 2-CHLORO-5-FLUOROQUINOLINE
• CAS NO: 455955-27-8
• Molecular Formula: C₉H₅ClFN
• Molecular Weight: 181.59
• Mol File: 455955-27-8.mol

Chemical Properties

• Boiling Point: 271.3±20.0 °C(Predicted)
• Appearance: /
• Density: 1.366±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -0.66±0.50(Predicted)
• CAS DataBase Reference: 2-CHLORO-5-FLUOROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-5-FLUOROQUINOLINE(455955-27-8)
• EPA Substance Registry System: 2-CHLORO-5-FLUOROQUINOLINE(455955-27-8)

Safety Data

• Hazardous Substances Data: 455955-27-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-fluoroquinoline is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential applications in treating bacterial and fungal infections.
Used in Agrochemical Industry:
In the agrochemical sector, 2-chloro-5-fluoroquinoline serves as an intermediate for the production of compounds that exhibit antibacterial and antifungal properties. These compounds are essential for protecting crops from diseases and ensuring agricultural productivity.
Used in Organic Compounds Synthesis:
2-Chloro-5-fluoroquinoline is also employed in the synthesis of other organic compounds, contributing to the advancement of organic chemistry and the creation of novel materials with diverse applications.
Used in Research and Development:
Due to its biological and pharmacological properties, 2-chloro-5-fluoroquinoline is a valuable compound in research and development. It aids scientists in exploring new avenues for drug discovery and understanding the mechanisms of action for potential therapeutic agents.
Used as Antibacterial and Antifungal Agent:
2-Chloro-5-fluoroquinoline has potential applications as an antibacterial and antifungal agent. Its ability to disrupt microbial DNA replication makes it a promising candidate for the development of new antimicrobial drugs to combat resistant strains of bacteria and fungi.

Upstream product

• 394-69-4 5-fluoroquinoline 
• 611-34-7 5-Aminoquinoline 
• 612-62-4 2-Chloroquinoline 
• 2338-73-0 5-Fluor-chinolin-N-oxid 

Downstream Products

• 1174197-78-4 5-fluoro-2-phenylquinoline 

Relevant articles and documents

Elemental fluorine Part 15. Selective direct fluorination of quinoline derivatives

Direct fluorination of various quinoline derivatives in acidic reaction media gives fluorinated quinoline products arising from electrophilic substitution processes.

Synthesis of a fluorine-18-labelled derivative of 6-nitroquipazine, as a radioligand for the in vivo serotonin transporter imaging with PET.

Considerable efforts have been engaged in the design, synthesis and pharmacological characterization of radioligands for imaging the serotonin transporter, based on its implication in several neuropsychiatric diseases, such as depression, anxiety and schizophrenia. In the 5-halo-6-nitroquipazine series, the fluoro derivative has been designed for positron emission tomography (PET). The corresponding 5-iodo-, 5-bromo- and 5-chloro N-Boc-protected quipazines as labelling precursors, as well as 5-fluoro-6-nitroquipazine as a reference compound have been synthesized. 5-[(18)F]Fluoro-6-nitroquipazine has been radiolabelled with fluorine-18 (positron-emitting isotope, 109.8 min half-life) by nucleophilic aromatic substitution from the corresponding N-Boc protected 5-bromo- and 5-chloro-precursors using K[(18)F]F-K(222) complex in DMSO by conventional heating (145 degrees C, 2 min) or microwave activation (50 W, 30-45 s), followed by removal of the protective group with TFA. Typically, 15-25 mCi (5.5-9.2 GBq) of 5-[(18)F]fluoro-6-nitroquipazine (1-2 Ci/micromol or 37-72 GBq/micromol) could be obtained in 70-80 min starting from a 550-650 mCi (20.3-24.0 GBq) aliquot of a cyclotron [(18)F]F(-) production batch (2.7-3.8% non decay-corrected yield based on the starting [(18)F]fluoride). Ex vivo studies (biodistribution in rat), as well as PET imaging (in monkey) demonstrated that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) readily crossed the blood brain barrier and accumulated in the regions rich in 5-HT transporter (frontal- and posterial cortex, striata). However, the low accumulation of the tracer in the thalamus (rat and monkey) as well as the comparable displacement of the tracer observed with both citalopram, a -HT re-uptake inhibitor and maprotiline, a norepinephrine re-uptake inhibitor (rat), indicate that 5-[(18)F]fluoro-6-nitroquipazine ([(18)F]-1d) does not have the suggested potential for PET imaging of the serotin transporter (SERT).

II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-{4-[(7-chloro-2-quinoxalinyl)oxylphenoxy}propionic acid (XK469)

XK469 (1) is among the most highly and broadly active antitumor agents to have been evaluated in our laboratories. Subsequent developmental studies led to the entry of (R)-(+) 1 (NSC 698215) into phase 1 clinical trials (NIH UO1-CA62487). The antitumor me